Concepedia

C.S. Denlinger

CD

Statistics

Publications

11

Citations

296

H-Index

11

Active since

2005

Affiliations

Fox Chase Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Indiana University Health

Indiana University – Purdue University Indianapolis

C.S. Denlinger is an author at Fox Chase Cancer Center specializing in pharmacology, medicine, and oncology.

Publications per year

2005–2021

11

Publications

11

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Ramaswamy Govindan, Marwan Fakih, Timothy Price et al. · Annals of Oncology · 2019 · 41 citations · Full text

, , +12

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma

Matteo Simonelli, Paolo Andrea Zucali, Armando Santoro et al. · Annals of Oncology · 2016 · 39 citations · Full text

, , +13

OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC

Ramaswamy Govindan, Marwan Fakih, T.J. Price et al. · Journal of Thoracic Oncology · 2019 · 34 citations

, , +7

1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)

Geoffrey Y. Ku, Elena Elimova, C.S. Denlinger et al. · Annals of Oncology · 2021 · 31 citations · Full text

, , +9

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

C.S. Denlinger, Lori J. Goldstein · Breast Diseases A Year Book Quarterly · 2007 · 29 citations

, , +16

1–5 of 11